Incyte (INCY) Stock Buyback History
TTM buyback yield 0.14% · Shareholder yield (TTM) 0.14%.
INCY
TTM buyback yield
0.14%
Shareholder yield (TTM)
0.14%
5Y share count change
-8.0%
TTM buyback spend
$25.98M
SBC coverage (TTM)
0.14x
YoY change in spend
-99.0%
5Y CAGR of spend
N/A
Peak year (2024)
$2.00B
Cumulative spend
$2.03B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Incyte (INCY) repurchased about $25.98M of stock over the trailing twelve months.
- Diluted share count is down 8.0% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 0.14× — repurchases only partially offset SBC dilution.
- TTM repurchases used about 2% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $19.10M | $249.35M | −$230.25M | 0.20B | -4.7% | 0.10% |
| 2024 | $2.00B | $266.06M | $1.74B | 0.21B | -6.8% | 15.03% |
| 2023 | $0.00 | $215.89M | −$215.89M | 0.23B | 0.9% | — |
| 2022 | $0.00 | $188.42M | −$188.42M | 0.22B | 0.8% | — |
| 2021 | $0.00 | $183.01M | −$183.01M | 0.22B | 1.8% | — |
| 2020 | $0.00 | $177.88M | −$177.88M | 0.22B | 0.2% | — |
| 2019 | $0.00 | $166.59M | −$166.59M | 0.22B | 0.9% | — |
| 2018 | $0.00 | $148.15M | −$148.15M | 0.22B | 5.4% | — |
| 2017 | $0.00 | $133.06M | −$133.06M | 0.20B | 5.4% | — |
| 2016 | $0.00 | $96.20M | −$96.20M | 0.19B | 3.6% | — |
| 2015 | $0.00 | $69.87M | −$69.87M | 0.19B | 11.5% | — |
| 2014 | $0.00 | $62.16M | −$62.16M | 0.17B | 13.2% | — |
| 2013 | $0.00 | $38.40M | −$38.40M | 0.15B | 14.4% | — |
| 2012 | $0.00 | $38.49M | −$38.49M | 0.13B | 3.5% | — |
| 2011 | $0.00 | $28.98M | −$28.98M | 0.13B | 3.1% | — |
| 2010 | $0.00 | $14.86M | −$14.86M | 0.12B | 18.2% | — |
| 2009 | $0.00 | $9.98M | −$9.98M | 0.10B | 14.7% | — |
| 2008 | $0.00 | $15.03M | −$15.03M | 0.09B | 6.7% | — |
| 2007 | $0.00 | $8.89M | −$8.89M | 0.08B | 0.5% | — |
| 2006 | $0.00 | $8.89M | −$8.89M | 0.08B | 0.6% | — |
| 2005 | $0.00 | $186.00K | −$186.00K | 0.08B | 11.8% | — |
| 2004 | $0.00 | $463.00K | −$463.00K | 0.07B | 4.5% | — |
| 2003 | $105.00K | $4.10M | −$3.99M | 0.07B | 5.9% | 0.02% |
| 2002 | $5.72M | $4.10M | $1.63M | 0.07B | 1.8% | 1.86% |
| 2001 | $0.00 | $0.00 | $0.00 | 0.07B | 4.7% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 0.06B | 12.3% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 0.06B | -2.6% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.06B | 8.9% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.05B | 32.7% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.04B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Incyte (INCY) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Incyte (INCY)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Incyte (INCY)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $19.10M | -99.0% | -$1.99B | ||
| 2024 | $2.00B | — | +$2.00B | ||
| 2023 | $0 | — | $0 | ||
| 2022 | $0 | — | $0 | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | — | $0 | ||
| 2019 | $0 | — | $0 | ||
| 2018 | $0 | — | $0 | ||
| 2017 | $0 | — | $0 | ||
| 2016 | $0 | — | $0 | ||
| 2015 | $0 | — | $0 | ||
| 2014 | $0 | — | $0 | ||
| 2013 | $0 | — | $0 | ||
| 2012 | $0 | — | $0 | ||
| 2011 | $0 | — | $0 | ||
| 2010 | $0 | — | $0 | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | — | $0 | ||
| 2007 | $0 | — | $0 | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | — | $0 | ||
| 2004 | $0 | -100.0% | -$105,000 | ||
| 2003 | $105,000 | -98.2% | -$5.62M | ||
| 2002 | $5.72M | — | +$5.72M | ||
| 2001 | $0 | — | $0 | ||
| 2000 | $0 | — | $0 | ||
| 1999 | $0 | — | $0 | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | — | — |
Incyte (INCY) most recent annual buyback spend stands at $19.10M (2025) – plunged 99.0% year-over-year.
Between 2024 and 2025, Incyte buyback spend plunged 99.0%, falling from $2.00B to $19.10M.
The highest annual buyback spend of $2.00B was reported in 2024. The lowest in the available history was $0 in 1993.
Among 8 Healthcare peers, Incyte (INCY) ranks 8th; the peer median for buyback spend is $2.75B.
Incyte Buyback Spend 2025: $19.10M
Incyte buyback spend in 2025 was $19.10M, plunged 99.0% below 2024.
Incyte Buyback Spend 2024: $2.00B
Incyte buyback spend in 2024 was $2.00B.
Incyte Buyback Spend 2023: $0
Incyte buyback spend in 2023 was $0.
Incyte Buyback Spend 2022: $0
Incyte buyback spend in 2022 was $0.
Incyte Buyback Spend 2021: $0
Incyte buyback spend in 2021 was $0.
See more financial history for Incyte (INCY).
Sector peers by buyback spend
Companies in the same sector as Incyte, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.14×.
Capital allocation mix
How Incyte splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.45B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Incyte's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Incyte buy back its own stock?
Yes, Incyte (INCY) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Incyte spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $25.98M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Incyte's buyback yield?
TTM buyback yield is about 0.14% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Incyte's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.14% combined (TTM-based where available).
Is Incyte diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Incyte's share count changed?
Diluted weighted average shares changed by about -8.0% over roughly five fiscal years (annual income statement data).
What is Incyte's buyback spend?
Latest reported buyback spend for Incyte (INCY) is $25.98M (period ending March 31, 2026).
How has Incyte buyback spend changed year-over-year?
Incyte (INCY) buyback spend changed -99.0% year-over-year on the latest annual filing.
When did Incyte buyback spend hit its highest annual value?
Incyte buyback spend reached its highest annual value of $2.00B in 2024.
What was Incyte buyback spend in 2024?
Incyte (INCY) buyback spend in 2024 was $2.00B.
What was Incyte buyback spend in 2025?
Incyte (INCY) buyback spend in 2025 was $19.10M.
Explore more
INCY Overview
Company profile, financial tools, and key metrics
INCY Revenue Counter
Earns $170.00 every second. See per minute, hour, and day.
INCY Earnings Counter
Earns $45.40 per second net profit. See per minute, hour, and day.
INCY Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
INCY What If Invested
What if you had invested $1,000? See historical returns from any date.
INCY How It Makes Money
Discover visual breakdown of $5.36B in revenue — where it comes from and where it goes.
INCY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
INCY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
INCY Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
INCY Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
INCY Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.